Previous 10 | Next 10 |
2024-05-07 11:56:08 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Madrigal Pharmaceuticals (NASDAQ: MDGL ) just reported results for the first quarter of 2024. Madrigal Pharmaceuticals reported earnings per share of -$7.38. This was belo...
2024-05-07 11:24:02 ET Madrigal Pharmaceuticals (MDGL) Q1 2024 Results Conference Call May 07, 2024 8:00 AM ET Company Participants Tina Ventura - Chief IRO Bill Sibold - CEO Mardi Dier - CFO Conference Call Participants Yasmeen Rahimi - Piper Sandler...
2024-05-07 10:44:37 ET More on Madrigal Pharmaceuticals Madrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-Label Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage Madrigal: Accelerated Rezdiffra Approval Puts It In The NAS...
2024-05-07 07:04:22 ET More on Madrigal Pharmaceuticals Madrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-Label Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage Madrigal: Accelerated Rezdiffra Approval Puts It In The NAS...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...
On March 14, 2024, received U.S. FDA approval of Rezdiffra™ (resmetirom) for the treatment of patients with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis In April 2024, product shipped and first patients received Rezdiffra, the first and ...
2024-05-06 11:08:27 ET Major earnings expected before the bell on Tuesday include: BP p.l.c. ( BP ) Datadog ( DDOG ) The Walt Disney ( DIS ) Duke Energy ( DUK ) Nikola ( NKLA ) Read the full article on Seeking Alpha For further details...
2024-05-06 10:57:03 ET More on Madrigal Pharmaceuticals Madrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-Label Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage Madrigal: Accelerated Rezdiffra Approval Puts It In The NAS...
2024-04-30 16:30:23 ET Summary MDGL has launched Rezdiffra, the first drug approved for nonalcoholic steatohepatitis (NASH). Rezdiffra faces competition from potential off-label use of GLP-1RA drugs like semaglutide and tirzepatide, but there is potential for combination therapy t...
CONSHOHOCKEN, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- The Madrigal team is shocked and saddened to learn of the passing of Dr. Stephen Harrison. We offer our deepest condolences to Stephen’s family for their loss. Stephen was a colleague and friend to so many of us at Madrigal. H...
News, Short Squeeze, Breakout and More Instantly...
Madrigal Pharmaceuticals Inc. Company Name:
MDGL Stock Symbol:
NASDAQ Market:
Madrigal Pharmaceuticals Inc. Website:
2024-06-30 12:02:00 ET Madrigal Pharmaceuticals (NASDAQ: MDGL) is at a moment of great opportunity, and there's a decent chance that its shareholders will feel good about their investments over the next few years. After commercializing its first medicine, which treats a condition no...
2024-06-16 12:05:00 ET If you're eyeing an investment in Madrigal Pharmaceuticals (NASDAQ: MDGL) , now's the time to imagine a representative of Eli Lilly (NYSE: LLY) interrupting your train of thought by saying something along the lines of, "Not so fast." While the biotech ...
2024-06-15 09:45:00 ET Madrigal Pharmaceuticals (NASDAQ: MDGL) is in a position that most other biotechs envy. Its first medicine just hit the market, sales are due to start rolling in, and there aren't any other companies that can slow it down -- for now, that is. By mid-2027, ...